SONG Qi-bin, WANG Qi, HU Wei-guo. Association of XPD Lys751Gln with Clinical Outcome of Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-AnalysisJ. Journal of Evidence-Based Medicine, 2013, 13(4): 236-241. DOI: 10.3969/j.issn.1671-5144.2013.04.013
Citation:
SONG Qi-bin, WANG Qi, HU Wei-guo. Association of XPD Lys751Gln with Clinical Outcome of Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-AnalysisJ. Journal of Evidence-Based Medicine, 2013, 13(4): 236-241. DOI: 10.3969/j.issn.1671-5144.2013.04.013
SONG Qi-bin, WANG Qi, HU Wei-guo. Association of XPD Lys751Gln with Clinical Outcome of Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-AnalysisJ. Journal of Evidence-Based Medicine, 2013, 13(4): 236-241. DOI: 10.3969/j.issn.1671-5144.2013.04.013
Citation:
SONG Qi-bin, WANG Qi, HU Wei-guo. Association of XPD Lys751Gln with Clinical Outcome of Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-AnalysisJ. Journal of Evidence-Based Medicine, 2013, 13(4): 236-241. DOI: 10.3969/j.issn.1671-5144.2013.04.013
Association of XPD Lys751Gln with Clinical Outcome of Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis
No content published by the Journal of Evidence-Based Medicine may be reproduced or abridged without authorization. Please do not use or copy the layout and design of the journal without permission.
All articles published represent the opinions of the authors, and do not reflect the official policy of the Journal of Evidence-Based Medicine’ Sponsors or the Editorial Board, unless this is clearly specified.
Objective To evaluate the association between XPD Lys751Gln and the clinical outcome of platinum-based chemotherapy in advanced NSCLC and guide the clinical medication and individualized treatment. Methods A meta-analysis was used to analyze the association between XPD Lys751Gln and the clinical outcome in advanced NSCLC patients treated with platinum-based chemotherapy. Results A total of 15 case-control studies were included in the meta-analysis. The result showed no associations between XPD Lys751Gln and the clinical outcome of platinum-based chemotherapy in advanced NSCLC patients. The pooled OR values for Lys/Gln+Gln/Gln compared with Lys/Lys was 1.26（95%CI 0.96~1.66）. The pooled HR for death in patients with Lys/Gln+Gln/Gln was 1.06（95%CI 0.81~1.37）. In the subgroup analysis by ethnicity, no statistically differences were found between XPD Lys751Gln and survival in advanced NSCLC patients treated with platinum-based chemotheray. Conclusion The result of meta-analysis suggests that no association between XPD Lys751Gln and the clinical outcome of platinum-based chemotherapy in advanced NSCLC. Further studies are needed to validate the conclusion.
DownLoad: